Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$234.03
+3.9%
$231.30
$150.89
$250.74
$14.59B0.41692,104 shs169,736 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$68.28
-0.7%
$71.29
$31.77
$84.94
$13.37B1.022.72 million shs728,633 shs
Indivior PLC stock logo
INDV
Indivior
$40.20
+1.5%
$31.95
$10.63
$40.16
$4.89B0.92.35 million shs506,573 shs
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
$27.96
+2.5%
$27.06
$3.93
$83.60
$13.80B1.88333,876 shs27,162 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+1.97%+1.56%-1.73%+2.53%+31.94%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.32%-1.39%-5.97%-8.53%+79.96%
Indivior PLC stock logo
INDV
Indivior
+5.12%+14.99%+29.93%+15.29%+232.69%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
-6.35%-6.13%-11.46%-3.91%+2,726,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$234.03
+3.9%
$231.30
$150.89
$250.74
$14.59B0.41692,104 shs169,736 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$68.28
-0.7%
$71.29
$31.77
$84.94
$13.37B1.022.72 million shs728,633 shs
Indivior PLC stock logo
INDV
Indivior
$40.20
+1.5%
$31.95
$10.63
$40.16
$4.89B0.92.35 million shs506,573 shs
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
$27.96
+2.5%
$27.06
$3.93
$83.60
$13.80B1.88333,876 shs27,162 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+1.97%+1.56%-1.73%+2.53%+31.94%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+0.32%-1.39%-5.97%-8.53%+79.96%
Indivior PLC stock logo
INDV
Indivior
+5.12%+14.99%+29.93%+15.29%+232.69%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
-6.35%-6.13%-11.46%-3.91%+2,726,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2.95
Moderate Buy$291.5624.58% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.92
Moderate Buy$87.7128.47% Upside
Indivior PLC stock logo
INDV
Indivior
3.00
Buy$39.33-2.16% Downside
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest INDV, ASND, BBIO, and RGC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/29/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetBuy$95.00 ➝ $102.00
4/28/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Reiterated RatingOutperform$106.00
4/27/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Reiterated RatingBuy$100.00
4/16/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetBuy$262.00 ➝ $292.00
4/9/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Reiterated RatingOutperform$273.00
4/9/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Initiated CoverageOutperform$100.00
4/8/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UpgradeModerate Buy
3/27/2026
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
Reiterated RatingSell (E+)
3/18/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetOutperform$91.00 ➝ $106.00
3/17/2026
Indivior PLC stock logo
INDV
Indivior
DowngradeBuy (B-)Hold (C+)
3/16/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Initiated CoverageBuy$290.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M17.92N/AN/A($2.97) per share-78.80
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M26.63N/AN/A($10.77) per share-6.34
Indivior PLC stock logo
INDV
Indivior
$1.24B3.96$2.81 per share14.33($1.18) per share-34.07
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/AN/A$0.01 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M-$4.40N/A22.44N/A-30.85%N/A-19.63%5/7/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.78N/A145.27N/A-144.39%N/A-74.43%5/7/2026 (Estimated)
Indivior PLC stock logo
INDV
Indivior
$210M$1.9520.5911.26N/A19.44%-219.26%29.40%N/A
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
-$3.58MN/AN/AN/AN/AN/AN/AN/AN/A

Latest INDV, ASND, BBIO, and RGC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$0.21N/AN/AN/A$362.56 millionN/A
5/7/2026Q1 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.70N/AN/AN/A$178.64 millionN/A
4/30/2026Q1 2026
Indivior PLC stock logo
INDV
Indivior
$0.64$0.96+$0.32$3.45$272.84 million$317.00 million
3/31/2026Q1 2026
Indivior PLC stock logo
INDV
Indivior
N/A$0.96N/A$3.45N/A$317.00 million
2/27/2026Q4 2025
Indivior PLC stock logo
INDV
Indivior
$0.65$0.82+$0.17$3.95$305.62 million$358.00 million
2/24/2026Q4 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.75-$1.00-$0.25-$1.00$150.71 million$154.18 million
2/12/2026Q4 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$0.06-$0.64-$0.58-$0.65$285.35 million$290.38 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Indivior PLC stock logo
INDV
Indivior
N/AN/AN/AN/AN/A
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.04
0.76
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
2.77
2.68
Indivior PLC stock logo
INDV
Indivior
N/A
0.86
0.66
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Indivior PLC stock logo
INDV
Indivior
60.33%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
0.13%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Indivior PLC stock logo
INDV
Indivior
0.74%
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.81 million167.94 millionOptionable
Indivior PLC stock logo
INDV
Indivior
1,051121.92 million121.02 millionNot Optionable
Regencell Bioscience Holdings Limited stock logo
RGC
Regencell Bioscience
10494.49 millionN/AN/A

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$234.03 +8.75 (+3.89%)
As of 12:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$68.28 -0.51 (-0.73%)
As of 12:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Indivior stock logo

Indivior NASDAQ:INDV

$40.20 +0.61 (+1.54%)
As of 12:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Regencell Bioscience stock logo

Regencell Bioscience NASDAQ:RGC

$27.96 +0.69 (+2.53%)
As of 12:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.